PDCD1 and non-small cell lung carcinoma: The positive clinical outcomes and tolerable safety profile of the frontline treatment regimen featuring camrelizumab, an anti-PD-1, in combination with low-dose apatinib, an angiogenesis inhibitor, has been revealed for previously untreated patients with advanced non-squamous NSCLC (145).